Premium
O3‐04–04: Cognition in the study of tamoxifen and raloxifene (Co‐STAR)
Author(s) -
Legault Claudine,
Resnick Susan,
Hogan Patricia,
Maki Pauline,
Bevers Therese B.,
Shumaker Sally
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.435
Subject(s) - boston naming test , memory span , psychology , wechsler adult intelligence scale , medicine , trail making test , verbal fluency test , breast cancer , verbal learning , audiology , cognition , clinical psychology , psychiatry , neuropsychology , cancer , working memory
Impression of Change (ADCS-CGIC), the Alzheimer’s Disease Activities of Daily Living International Scale (ADL-IS), the Quality of Life Scale for People with Dementia (DEMQOL-Proxy), and the Verbal Fluency Test were secondary outcomes. Results: Of the 404 patients evaluable for efficacy, 333 patients were prospectively diagnosed with Alzheimer’s disease (AD) and 71 with vascular dementia (VaD). Under EGb 761 treatment the SKT total score improved by -1.4 2.8 points in both AD and VaD subgroups, whereas the AD and VaD patients on placebo deteriorated by 0.3 2.7 points or remained unchanged, respectively (p 0.01 and p 0.05 for drug-placebo differences). The NPI total score improved by -2.9 5.9 points in AD patients and by -4.5 6.5 in VaD patients following EGb 761 treatment, whereas a deterioration by 0.2 6.2 and a slight improvement by -1.3 5.9 were observed in the corresponding sub-groups under placebo (p 0.01 and p 0.05 for drug-placebo differences). Significant drug-placebo differences were found for all secondary outcome variables with no major differences between AD and VaD subgroups, except for the DEMQOL-Proxy. Conclusions: EGb 761 distinctly improved cognitive functioning, non-cognitive symptoms and functional abilities in both AD and VaD, while the rates of adverse events in EGb 761 and placebo groups were essentially similar.